Table 1.
Description | Count in gene set | False discovery rate |
---|---|---|
Proteoglycans in cancer | 7 of 195 | 1.83e−08 |
Pathways in cancer | 9 of 515 | 1.83e−08 |
Signaling pathways regulating pluripotency of stem cells | 6 of 138 | 7.64e−08 |
Central carbon metabolism in cancer | 5 of 65 | 8.93e−08 |
MicroRNAs in cancer | 6 of 149 | 8.93e−08 |
EGFR tyrosine kinase inhibitor resistance | 5 of 78 | 1.67e−07 |
PI3K-Akt signaling pathway | 7 of 348 | 2.00e−07 |
Jak-STAT signaling pathway | 5 of 160 | 2.64e−06 |
MAPK signaling pathway | 5 of 293 | 3.07e−05 |
FoxO signaling pathway | 4 of 130 | 3.24e−05 |
Glioma | 3 of 68 | 0.00013 |
TNF signaling pathway | 3 of 108 | 0.00034 |
Transcriptional misregulation in cancer | 3 of 169 | 0.00097 |
mTOR signaling pathway | 3 of 148 | 0.00070 |
VEGF signaling pathway | 2 of 59 | 0.0027 |
TGF-beta signaling pathway | 2 of 83 | 0.0046 |
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database, used to integrate and interpret large-scale data from genome sequencing and other high-throughput experimental techniques such as proteomics analysis, has revealed the top pathways in which these interactions are involved. Abbreviations: EGFR, epidermal growth factor receptor; PI3K-AKT, phosphoinositide 3-kinase-AK strain transforming; Jak-STAT, Janus kinase and signal transducer and activator of transcription; MAPK, mitogen-activated protein kinase; FOXO, class O of forkhead box transcription factors; TNF, tumor necrosis factor; mTOR, mechanistic (formerly “mammalian”) target of rapamycin; VEGFR, vascular endothelial growth factor receptor; TGF-β, transforming growth factor β.